Allergy Therapeutics plc (LON:AGY)‘s stock had its “buy” rating reissued by equities researchers at Panmure Gordon in a research note issued to investors on Monday. They currently have a GBX 53 ($0.69) price target on the stock. Panmure Gordon’s price objective would indicate a potential upside of 197.09% from the stock’s current price.
Other equities analysts have also issued reports about the company. Numis Securities Ltd started coverage on Allergy Therapeutics plc in a research report on Wednesday, September 21st. They set a “buy” rating and a GBX 37 ($0.48) price objective on the stock. Stifel Nicolaus restated a “buy” rating and set a GBX 72 ($0.94) target price on shares of Allergy Therapeutics plc in a report on Friday, July 8th.
Shares of Allergy Therapeutics plc (LON:AGY) opened at 17.35 on Monday. Allergy Therapeutics plc has a 12-month low of GBX 17.29 and a 12-month high of GBX 34.82. The stock’s 50 day moving average price is GBX 18.77 and its 200 day moving average price is GBX 22.69. The company’s market cap is GBX 97.08 million.
Allergy Therapeutics plc Company Profile
Allergy Therapeutics Plc is a United Kingdom-based pharmaceutical company. The Company focuses on the treatment and prevention of allergy with aluminum free products. It provides information to healthcare professionals about the prevention, diagnosis and treatment of allergic conditions with focus on allergy vaccination, which is also known as specific immunotherapy or desensitization therapy.
Receive News & Ratings for Allergy Therapeutics plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergy Therapeutics plc and related companies with MarketBeat.com's FREE daily email newsletter.